Skip to Main Content

Paper Details

Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis.
Gastroenterology
223
2018
Author NameAffiliation
Stephen A HarrisonPinnacle Clinical Research
Gopinath M Subramanian
Zachary GoodmanInova Fairfax Hospital
Jaime BoschBern University, University of Barcelona
Arun J SanyalVirginia Commonwealth University
  • 1 - 5

Datasets

Release 1.2